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In recent years, several HIV-1 vaccine candidates have been tested that employ a recombinant 
adenovirus (rAd5) to express HIV-1 genes. While none of these vaccines elicited a protective 
immune response, considerable effort has gone into studying the immune response elicited by each 
vaccine. In a recent study published in PLoS Pathogens, Drs. Tomer Hertz and Peter Gilbert and 
their collaborators conducted a meta-analysis of the T-cell epitopes elicited at a population level by 
two different vaccines across three separate trials, and find that vaccine-elicited responses cluster in 
“hotspots”. These hotspots are variable but may be predicted based on patient HLA alleles (a 
component of the immune system responsible for displaying antigens on the cell surface). This work 
has the potential to identify and prioritize potentially effective candidate vaccines earlier in the testing 
process. 
Hertz et al. analyzed the cytotoxic T-cell response elicited in 177 individuals across three vaccine 
trials, two of which used the same Merck rAd5-gag/pol/nef vaccine, and compared these responses 
to 372 patients with chronic HIV infection. The team constructed population-level epitope maps for 
each cohort by tallying the number of cytotoxic T-cell responses at each position along an HIV-1 
protein. Using these maps, the authors found that immune responses in all three vaccine trials and 
in naturally infected patients were clustered around immunodominant hotspots. However, the 
targeted hotspots were significantly different between the three vaccine trials, even between the two 
trials which used the same vaccine. The team next sought to determine whether the differences in 
these trials could be due to differences in the distribution of HLA alleles. They compared matched 
HLA across the three groups, and found that while statistical differences in hotspot locations 
targeted in the HIV-1 protein Gag did not hold, the differences in hotspots found in the HIV-1 
proteins Nef and Pol across the three vaccine trials remained, suggesting that the observed 
differences in hotspots are not solely due to HLA differences between the three vaccine trials. 
The authors next characterized targeted epitopes relative to naturally infected patients, and found 
that some vaccine-induced hotspots targeted epitopes that were not often targeted in chronically 
infected patients. In addition, some of the vaccine-induced hotspots targeted non-conserved sites in 
the HIV-1 proteins preferentially. For example, non-conserved Gag epitopes were preferentially 
targeted in all of the vaccine trials, but not in naturally infected patients. 
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Several of the hotspots identified in this study were targeted by multiple HLA alleles; therefore, Hertz 
et al. sought to determine whether HLA binding predictor algorithms (Lin, et al., 2008) may be used 
to predict population-level epitope hotspots in a candidate vaccine. The team pooled predicted 
epitope targets for all possible HLA alleles into a single prediction map, and then compared these 
maps to the population-based epitope maps they generated for the vaccine trials. The predicted 
maps were significantly correlated to the observed responses to Gag, Pol, and Nef, but not to Env 
responses. Moreover, the predicted maps identified nearly all the experimentally determined 
immunodominant epitopes. However, the predicted maps also contained other immunodominant 
epitopes that were not observed in the vaccine trials, likely because HLA predictors focus solely on 
HLA binding, and do not take into account other factors such as epitope half-life and T-cell receptor 
avidity. 
This study found that immunodominant epitopes elicited by each vaccine trial were different, even 
when the same vaccine was employed in two different trials. However, the immunodominant 
hotspots observed in each vaccine trial were also identified by HLA predictors. “Coupled with novel 
data about which immune responses against the HIV virus are protective, this approach may allow 
[us] to compare and rank different vaccine candidates in earlier stages of clinical development,” said 
Dr. Tomer. 
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Image modified from Hertz, et al., 2013. 
Population-based epitope map of IFN-γ responses to HIV-1 Gag from patients in 
the HVTN 502/Step trial. Hotspots are indicated by dashed lines. 
 
